Immune checkpoint inhibitors‐induced neuromuscular toxicity: From pathogenesis to treatment-Reference-Cited by-同舟云学术

Immune checkpoint inhibitors‐induced neuromuscular toxicity: From pathogenesis to treatment

Published:2019-10 Issue:S2 Volume:24 Page:
ISSN:1085-9489
Container-title:Journal of the Peripheral Nervous System
language:en
Short-container-title:J Peripher Nerv Syst

Author:

Psimaras Dimitri¹²³^ORCID,Velasco Roser⁴⁵⁶^ORCID,Birzu Cristina¹²³,Tamburin Stefano⁷^ORCID,Lustberg Maryam⁸,Bruna Jordi⁴⁵⁶,Argyriou Andreas A.⁹

Affiliation:

1. AP‐HP, Hôpitaux Universitaires La Pitié Salpêtrière—Charles Foix, Service de Neurologie Mazarin Paris France

2. Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM Paris France

3. OncoNeuroTox Group, Center for Patients with Neurological Complications of Oncologic TreatmentsHôpitaux Universitaires Pitié‐Salpetrière‐Charles Foix et Hôpital Percy Paris France

4. Unit of Neuro‐OncologyHospital Universitari de Bellvitge‐Institut Català D'Oncologia L'Hospitalet, IDIBELL Barcelona Spain

5. Department of Cell Biology, Physiology and Immunology, Institute of NeurosciencesUniversitat Autònoma de Barcelona Barcelona Spain

6. Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED) Barcelona Spain

7. Department of Neurosciences, Biomedicine and Movement SciencesUniversity of Verona Verona Italy

8. Division of Medical Oncology, Department of Internal MedicineThe Ohio State University Comprehensive Cancer Columbus Ohio

9. Department of Neurology“Saint Andrew's” State General Hospital of Patras Patras Greece

Publisher

Wiley

Subject

Neurology (clinical),General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jns.12339

Reference101 articles.

1. Advances in personalized cancer immunotherapy;Kakimi K;Breast Cancer,2017

2. Cancer immunotherapy: opportunities and challenges in the rapidly evolving clinical landscape;Emens LA;Eur J Cancer,2017

3. Immune checkpoint blockade therapy for cancer: an overview of FDA‐approved immune checkpoint inhibitors;Hargadon KM;Int Immunopharmacol,2018

4. Cemiplimab: first global approval;Markham A;Drugs,2018

5. Nivolumab plus ipilimumab in advanced melanoma;Wolchok JD;N Engl J Med,2013

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Myocarditis, Myositis, and Myasthenia Gravis Overlap Syndrome Associated with Immune Checkpoint Inhibitors: A Systematic Review;Diagnostics;2024-08-16

2. Unravelling the Acute, Chronic and Steroid-Refractory Management of High-Grade Neurological Immune-Related Adverse Events: A Call to Action;Brain Sciences;2024-07-29

3. Immune checkpoint inhibitors and neurotoxicity: a focus on diagnosis and management for a multidisciplinary approach;Expert Opinion on Drug Safety;2024-06-03

4. Facial palsy after administration of immune checkpoint inhibitors: case report, literature review and clinical care management;Frontiers in Immunology;2024-03-22

5. Neurological manifestations in malignant melanoma;Practical Neurology;2024-02-20